Implantica announces positive feedback received from U.S. FDA of the RefluxStop™ PMA Module 2 submission

Contributed by: PR Newswire

Tags

IMPLANTICA-FDA-REVIEW

More Like This

Implantica submits FDA PMA application Clinical Module 2 for RefluxStop™ for U.S. market approval

Implantica announces Module 1 is accepted and closed by FDA in the PMA application for RefluxStop™

Implantica announces continuing progress in modular PMA application to FDA for RefluxStop™

Implantica announces finalization of remarkable 5-year pivotal CE mark study results and gears up for the Module 2 submission of PMA application to FDA for RefluxStop™

Implantica submits U.S. FDA Premarket Approval (PMA) application for RefluxStop® (first module)

Implantica publishes Interim Report January - June 2024 (Q2)

Implantica publishes Year-end Report, January - December 2024 (Q4)

Implantica announces highly successful 2024 American Foregut Society meeting where RefluxStop® received remarkable pre-launch market feedback